Rice Hall James & Associates LLC Trims Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Rice Hall James & Associates LLC cut its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 225,923 shares of the medical instruments supplier’s stock after selling 6,776 shares during the period. LeMaitre Vascular comprises approximately 1.1% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 23rd biggest holding. Rice Hall James & Associates LLC’s holdings in LeMaitre Vascular were worth $18,589,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Shaker Investments LLC OH lifted its holdings in shares of LeMaitre Vascular by 1.3% in the 1st quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock valued at $906,000 after buying an additional 169 shares during the period. GAMMA Investing LLC grew its holdings in LeMaitre Vascular by 57.0% during the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 199 shares during the period. nVerses Capital LLC raised its position in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 200 shares in the last quarter. Albion Financial Group UT raised its position in LeMaitre Vascular by 5.6% during the first quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock valued at $264,000 after acquiring an additional 212 shares in the last quarter. Finally, Texas Permanent School Fund Corp lifted its holdings in LeMaitre Vascular by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock valued at $1,151,000 after acquiring an additional 225 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on LMAT. Roth Mkm reaffirmed a “buy” rating and set a $100.00 target price on shares of LeMaitre Vascular in a report on Friday, May 31st. Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st. Barrington Research increased their target price on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. JMP Securities upped their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Finally, Lake Street Capital initiated coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $94.40.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $86.34 on Wednesday. The stock has a market capitalization of $1.94 billion, a P/E ratio of 57.18, a PEG ratio of 2.32 and a beta of 0.88. The business has a 50 day simple moving average of $85.92 and a two-hundred day simple moving average of $76.89. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The firm had revenue of $55.85 million for the quarter, compared to the consensus estimate of $54.98 million. During the same period last year, the firm posted $0.37 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.85 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were given a $0.16 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.74%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the transaction, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 12,976 shares of the business’s stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $86.07, for a total transaction of $1,116,844.32. Following the completion of the transaction, the chief executive officer now owns 1,985,358 shares in the company, valued at $170,879,763.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,251 shares of company stock valued at $3,714,994. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.